FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Franck's Lab Inc., d.b.a. Franck's Compounding Lab Lidocaine Hcl/Epinephrine In Bss Recall

LIDOCAINE HCL/EPINEPHRINE IN BSS - P

Franck's Lab Inc., d.b.a. Franck's Compounding Lab · Ocala, FL

Risk level
Class II
Reported by FDA
Aug 22, 2012
Recall ID
D-1560-2012
Check your lot numberHow we source this data

Summary

Franck's Lab Inc., d.b.a. Franck's Compounding Lab recalled Lidocaine Hcl/Epinephrine In Bss starting May 21, 2012. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1560-2012 on Aug 22, 2012. Reason: Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Product description

LIDOCAINE HCL/EPINEPHRINE IN BSS - P.F., SULFITE-FREE 0.75%/0.025% INJECTABLE 24 ML 6 ML; LIDOCAINE HCL/EPINEPHRINE, P.F., SULFITE-FREE 2%/1:100,000 (0.001%) INJECTABLE 10 ML 40 ML; LIDOCAINE HCL/EPINEPHRINE. 2%/1:100,000 (0.001%) INJECTABLE 100 ML 1200 ML 300 ML 80 ML; LIDOCAINE/EPINEPHRINE 1%/0.00025% OPHTHALMIC 30 ML 60 ML 90 ML; LIDOCAINE/EPINEPHRINE, P.F. (FOR DILUTION WITH BSS+) 1.71%/0.057% OPHTHALMIC 14 ML 7 ML (8 DIFFERENT PRODUCTS)

Lot numbers, UPCs & expiration codes

Rx #'s: 0397942 0397942 0395256 0395256 0387634 0397219 0400108 0387634 0370170 0370170 0370170 0389690 0389690

Where it was sold

Nationwide, Bahamas, Columbia, Dominican Republic, Grand Cayman, Guatemala, Poland, Santo Domingo, Venezuela, West Indies

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1560-2012
Classification
Class II
Status
Terminated
Recall initiated
May 21, 2012
FDA report date
Aug 22, 2012
Quantity
15 units
Recall type
Voluntary: Firm initiated
Recalling firm
Franck's Lab Inc., d.b.a. Franck's Compounding Lab

Original FDA data

Every field from FDA enforcement report D-1560-2012, exactly as published.

Show all FDA fields
City
Ocala
State
FL
Status
Terminated
Country
United States
Event ID
62443
Address
1210 SW 33rd Avenue
Code information
Rx #'s: 0397942 0397942 0395256 0395256 0387634 0397219 0400108 0387634 0370170 0370170 0370170 0389690 0389690
Postal code
34474-5138
Report date
Aug 22, 2012
Product type
Drugs
Recall number
D-1560-2012
Classification
Class II
Recalling firm
Franck's Lab Inc., d.b.a. Franck's Compounding Lab
Product quantity
15 units
Termination date
Aug 15, 2014
Reason for recall
Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.
Voluntary / mandated
Voluntary: Firm initiated
Product description
LIDOCAINE HCL/EPINEPHRINE IN BSS - P.F., SULFITE-FREE 0.75%/0.025% INJECTABLE 24 ML 6 ML; LIDOCAINE HCL/EPINEPHRINE, P.F., SULFITE-FREE 2%/1:100,000 (0.001%) INJECTABLE 10 ML 40 ML; LIDOCAINE HCL/EPINEPHRINE. 2%/1:100,000 (0.001%) INJECTABLE 100 ML 1200 ML 300 ML 80 ML; LIDOCAINE/EPINEPHRINE 1%/0.00025% OPHTHALMIC 30 ML 60 ML 90 ML; LIDOCAINE/EPINEPHRINE, P.F. (FOR DILUTION WITH BSS+) 1.71%/0.057% OPHTHALMIC 14 ML 7 ML (8 DIFFERENT PRODUCTS)
Distribution pattern
Nationwide, Bahamas, Columbia, Dominican Republic, Grand Cayman, Guatemala, Poland, Santo Domingo, Venezuela, West Indies
Recall initiation date
May 21, 2012
Initial firm notification
Letter
Center classification date
Aug 10, 2012

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1560-2012, published Aug 22, 2012. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls